ALX Oncology Holdings Inc. (ALXO)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 6.10 |
| Open | 6.15 |
| Bid | 6.02 x 600 |
| Ask | 6.09 x 1100 |
| Day's Range | 5.99 - 6.38 |
| 52 Week Range | 3.94 - 17.83 |
| Volume | |
| Avg. Volume | 884,038 |
| Market Cap | 315.206M |
| Beta (5Y Monthly) | 1.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.71 |
| Earnings Date | Aug 08, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.00 |
ZacksIDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data
IDEAYA (IDYA) gains 15% on positive clinical data from its phase II study evaluating the 30 mg monotherapy expansion dose of IDE397 to treat MTAP-deletion urothelial and NSCLC patients.
ZacksAdicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag
Adicet (ACET) gains as the FDA grants the Fast Track designation to ADI-270 for the potential treatment of a form of kidney cancer. A phase I study for this indication is set to begin in 2024.
ZacksDianthus (DNTH) Gains 18% in the Past Month: Here's Why
Dianthus (DNTH) shares have rallied 18% in the past month on FDA clearance to initiate a phase II study on its lead candidate, DNTH103, to treat an autoimmune indication. Top-line data is expected in 2026.
© 2024 Yahoo. All rights reserved.